Filing Flows › Lenz Therapeutics (LENZ) › Guidance history
Lenz Therapeutics (LENZ) guidance history: what it guided and what it reported
Lenz Therapeutics gave guidance in 2 earnings releases on file since May 7, 2025. Its releases raised guidance once and lowered it 0 times.
Operating expenses
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2027 | $70.0M–$75.0M (Oct 28, 2026) | — | to be reported | — |
The latest quarter
Lenz Therapeutics, Q3 2026: revenue $3.4M (-73% year over year), operating margin -972.8%, net loss $31.0M, operating cash flow −$22.3M. The chart follows the revenue to costs, profit and cash.
Questions
Does Lenz Therapeutics beat its guidance?
Lenz Therapeutics gave guidance in 2 earnings releases on file since May 7, 2025. Its releases raised guidance once and lowered it 0 times.
How often does Lenz Therapeutics raise guidance?
Its earnings releases raised guidance once and lowered it 0 times since May 7, 2025.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.